{
  "symbol": "GILD",
  "year": 2024,
  "Period": "Y2024",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1619,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.222
  },
  "top_positive": [
    {
      "sent": "2022 Equity Incentive Plan (15) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (16) 10.5* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (17) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (18) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (19) 10.8* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (20) 10.9* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (21) 10.10* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022) (22) 10.11* Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2023) (23) 10.12* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018) (16) 10.13* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (24) 10.14* Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021) (21) 10.15* Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2022) (25) 10.16* Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants commencing in 2023) (18) 10.17* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (19) 10.18* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021) (20) 10.19* Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022) (22) 10.20* Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2023) (18) 10.21* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020) (19) 10.22* Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan ",
      "score": 0.9994
    },
    {
      "sent": "The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting: December 31, 2023 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 6 Other current liabilities $ 38 Foreign currency exchange contracts Other long-term assets \u2014 Other\u00a0long-term\u00a0obligations 7 Total derivatives designated as hedges 6 45 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 15 Total derivatives not designated as hedges 1 15 Total derivatives presented gross on the Consolidated Balance Sheets $ 7 $ 59 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments $ ( 7 ) $ ( 7 ) Cash collateral received / pledged \u2014 \u2014 Net amount (legal offset) $ \u2014 $ 52 70 December 31, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 59 Other current liabilities $ 26 Foreign currency exchange contracts Other long-term assets 1 Other\u00a0long-term\u00a0obligations 9 Total derivatives designated as hedges 59 35 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 1 Other current liabilities 7 Total derivatives not designated as hedges 1 7 Total derivatives presented gross on the Consolidated Balance Sheets $ 60 $ 42 Gross amounts not offset on the Consolidated Balance Sheets: Derivative financial instruments $ ( 36 ) $ ( 36 ) Cash collateral received / pledged \u2014 \u2014 Net amount (legal offset) $ 25 $ 7 The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements: Year Ended December 31, (in millions) 2023 2022 2021 Derivatives designated as hedges: Net (loss) gain recognized in Accumulated other comprehensive income (loss) $ ( 14 ) $ 150 $ 147 Net gain (loss) reclassified from Accumulated other comprehensive income (loss) into Product sales $ 58 $ 196 $ ( 67 ) Derivatives not designated as hedges: Net gain recognized in Other income (expense), net $ 57 $ 67 $ 21 The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensiv\ns) Amortized\u00a0Cost Fair Value Within one year $ 1,267 $ 1,262 After one year through five years 1,153 1,153 After five years through ten years 9 9 After ten years 2 2 Total $ 2,430 $ 2,426 Equity Securities The following table summarizes the classification of our equity securities on our Consolidated Balance Sheets: December 31, (in millions) 2023 2022 Equity securities measured at fair value: Cash and cash equivalents $ 4,465 $ 3,831 Prepaid and other current assets 1,086 473 Other long-term assets 656 943 Equity method investments and other equity investments without readily determinable fair values: Other long-term assets $ 340 $ 423 Total $ 6,547 $ 5,671 For our equity method investments in Galapagos and Arcus Biosciences, Inc.",
      "score": 0.9914
    },
    {
      "sent": "Securities Authorized For Issuance Under Equity Compensation Plans The following table provides certain information with respect to our equity compensation plans in effect as of December\u00a031, 2023: (in millions, except exercise price) Number of Common Shares to be Issued Upon Exercise of Outstanding Options and Rights (1) Weighted-average Exercise Price of Outstanding Options and Rights (1) Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) Plan Category (a) (b) (c) Equity compensation plans approved by security holders: 2022 Equity Incentive Plan 38.0 $ 69.38 82.3 Employee Stock Purchase Plan (2) 26.0 Total equity compensation plans approved by security holders 38.0 $ 69.38 108.3 Equity compensation plans not approved by security holders \u2014 $ \u2014 \u2014 Total 38.0 $ 69.38 108.3 ______________________________________________________ (1) Includes 24\u00a0million restricted stock units, performance share units and phantom shares.",
      "score": 0.9895
    }
  ],
  "top_negative": [
    {
      "sent": "DEBT AND CREDIT FACILITIES The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate December 31, 2023 December 31, 2022 Senior Unsecured September 2016 September 2023 2.50 % $ \u2014 $ 749 Senior Unsecured September 2020 September 2023 0.75 % \u2014 1,498 Senior Unsecured March 2014 April 2024 3.70 % 1,750 1,748 Senior Unsecured November 2014 February 2025 3.50 % 1,749 1,748 Senior Unsecured September 2015 March 2026 3.65 % 2,744 2,742 Senior Unsecured September 2016 March 2027 2.95 % 1,248 1,247 Senior Unsecured September 2020 October 2027 1.20 % 747 747 Senior Unsecured September 2020 October 2030 1.65 % 994 993 Senior Unsecured September 2023 October 2033 5.25 % 992 \u2014 Senior Unsecured September 2015 September 2035 4.60 % 993 993 Senior Unsecured September 2016 September 2036 4.00 % 743 742 Senior Unsecured September 2020 October 2040 2.60 % 988 988 Senior Unsecured December 2011 December 2041 5.65 % 996 996 Senior Unsecured March 2014 April 2044 4.80 % 1,737 1,736 Senior Unsecured November 2014 February 2045 4.50 % 1,734 1,733 Senior Unsecured September 2015 March 2046 4.75 % 2,222 2,221 Senior Unsecured September 2016 March 2047 4.15 % 1,729 1,728 Senior Unsecured September 2020 October 2050 2.80 % 1,478 1,477 Senior Unsecured September 2023 October 2053 5.55 % 988 \u2014 Total senior unsecured notes 23,834 24,088 Liability related to future royalties 1,153 1,141 Total debt, net 24,987 25,229 Less: Current portion of long-\n), alleging breach of three material transfer agreements (\u201cMTAs\u201d) related to the research underlying the HHS Patents and two clinical trial agreements (\u201cCTAs\u201d) by the U.S.",
      "score": -0.9918
    },
    {
      "sent": "DEBT AND CREDIT FACILITIES The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate December 31, 2023 December 31, 2022 Senior Unsecured September 2016 September 2023 2.50 % $ \u2014 $ 749 Senior Unsecured September 2020 September 2023 0.75 % \u2014 1,498 Senior Unsecured March 2014 April 2024 3.70 % 1,750 1,748 Senior Unsecured November 2014 February 2025 3.50 % 1,749 1,748 Senior Unsecured September 2015 March 2026 3.65 % 2,744 2,742 Senior Unsecured September 2016 March 2027 2.95 % 1,248 1,247 Senior Unsecured September 2020 October 2027 1.20 % 747 747 Senior Unsecured September 2020 October 2030 1.65 % 994 993 Senior Unsecured September 2023 October 2033 5.25 % 992 \u2014 Senior Unsecured September 2015 September 2035 4.60 % 993 993 Senior Unsecured September 2016 September 2036 4.00 % 743 742 Senior Unsecured September 2020 October 2040 2.60 % 988 988 Senior Unsecured December 2011 December 2041 5.65 % 996 996 Senior Unsecured March 2014 April 2044 4.80 % 1,737 1,736 Senior Unsecured November 2014 February 2045 4.50 % 1,734 1,733 Senior Unsecured September 2015 March 2046 4.75 % 2,222 2,221 Senior Unsecured September 2016 March 2047 4.15 % 1,729 1,728 Senior Unsecured September 2020 October 2050 2.80 % 1,478 \n&D intangible assets during those years, other than for the assessment described below, were 7.5 %, 7.5 % and 6.5 %, respectively.",
      "score": -0.9878
    },
    {
      "sent": "DEBT AND CREDIT FACILITIES The following table summarizes the carrying amount of our borrowings under various financing arrangements: (in millions) Carrying Amount Type of Borrowing Issue Date Maturity Date Interest Rate December 31, 2023 December 31, 2022 Senior Unsecured September 2016 September 2023 2.50 % $ \u2014 $ 749 Senior Unsecured September 2020 September 2023 0.75 % \u2014 1,498 Senior Unsecured March 2014 April 2024 3.70 % 1,750 1,748 Senior Unsecured November 2014 February 2025 3.50 % 1,749 1,748 Senior Unsecured September 2015 March 2026 3.65 % 2,744 2,742 Senior Unsecured September 2016 March 2027 2.95 % 1,248 1,247 Senior Unsecured September 2020 October 2027 1.20 % 747 747 Senior Unsecured September 2020 October 2030 1.65 % 994 993 Senior Unsecured September 2023 October 2033 5.25 % 992 \u2014 Senior Unsecured September 2015 September 2035 4.60 % 993 993 Senior Unsecured September 2016 September 2036 4.00 % 743 742 Senior Unsecured September 2020 October 2040 2.60 % 988 988 Senior Unsecured December 2011 December 2041 5.65 % 996 996 Senior Unsecured March 2014 April 2044 4.80 % 1,737 1,736\ned December\u00a031, 2023, 2022 and 2021, except as described in the \u201cIntangible Assets\u201d table above and under \u201c2022 IPR&D Impairment\u201d below.",
      "score": -0.9823
    }
  ],
  "forward_snippets": [
    "The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties that could result in delays or prevent completion of the development and approval of our product candidates.",
    "In 2023, we continued to invest in and advance our R&D pipeline across our therapeutic areas.",
    "In addition, we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas through strategic collaborations, in-licensing and acquisitions.",
    "to add additional early pipeline assets in oncology and inflammation, including rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology as well as mK2 for inflammatory diseases; and (ii) Tmunity Therapeutics, Inc.",
    "The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties that could result in delays or prevent completion of the development and approval of our product candidates."
  ]
}